SOLID TARGET TECHNOLOGY FOR MEDICAL CYCLOTRONS

Solid Target Manufacturing

Solid targetry for Tc-99m, Ga-68, Zr-89 and Cu-64 isotope production

 

Solid Target Manufacturing

Solid Target Transportation

Reliable and compact pneumatic transfer system for solid targets

QUANTM Irradiation System

Isotope Separation Systems

Dissolution and purification processes to extract isotopes for diagnostic imaging

 

INNOVATION EXCELLENCE

ARTMS™ Products is a leader in the development of novel technologies which enable the production of the world’s most-used diagnostic imaging isotopes. Our flagship product is the QUANTM99, a hardware and consumable system for producing Tc-99m on medical cyclotrons to enable cost-effective, decentralized, and local production of medical isotopes.

MEDICAL ISOTOPE PRODUCTION
NUCLEAR CHEMISTRY
QUALITY ANALYTICS
REGULATORY COMPLIANCE
INDUSTRY ENGAGEMENT

BREAKTHROUGH TECHNOLOGY

In 2007 & 2009 the world experienced shortages due to reactor outages, highlighting the vulnerability of the current supply chain. The shortages caused in significant price increases, delayed and canceled medical procedures and resulted in a decrease in patient care. In response, ARTMS Products Inc. developed an award-winning, first-to-market, locally deployable method for producing Tc-99m using existing, hospital-based medical cyclotrons. ARTMS holds the exclusive global commercialization rights to the award-winning and proprietary Canadian technology that addresses these challenges and offers the prospect of revolutionizing the nuclear medicine industry.

EXISTING SUPPLY

ARTMS PHILOSOPHY

IN THE NEWS

ARTMSTech

Researchers at the BC Cancer Agency in Vancouver and TRIUMF, the Canadian national particle and nuclear physics lab, have successfully produced vital supplies of Technetium-99m, a medical imaging isotope, using a retrofitted cyclotron, a type of particle accelerator already in […]

ARTMSTech

A Canadian-led team says that it has succeeded in proving the feasibility of using particle accelerators instead of nuclear reactors to produce a badly needed medical isotope. If health regulators approve the method, it will place supplies of the crucial […]

ARTMSTech

The first commercial shipment of medical isotopes produced using a new particle-accelerator-based technique has been made by scientists at the Canadian Light Source (CLS). Molybdenum-99 (Mo-99) decays to create technetium-99m (Tc-99m), which is used to tag radiopharmaceuticals and plays a […]

See all our news

AWARD WINNING LEADERSHIP

Dr. Paul Schaffer, CTO

Dr. Paul Schaffer is CTO of ARTMS Products and Head of TRIUMF's…

Charles S. Conroy, CEO

Mr. Conroy is the Chief Executive Officer (CEO) of ARTMS Products. Mr.…

Dr. Michael Cross, COO

Dr. Michael Cross PhD, MBA, is the Chief Operating Officer of ARTMS…

The prestigious NSERC Brockhouse Canada Prize was awarded in recognition of the outstanding interdisciplinary research involved in developing ARTMS medical isotope imaging technologies. The annual Prize was presented by His Excellency the Right Honourable David Johnston, the 28th Governor General of Canada.

PRESS RELEASES

PARTNERS

inline-flex

Lawson Health Research Institute | BC Cancer Agency | TRIUMF Innovations | TRIUMF | Centre for Probe Development and Commercialization